Ticker brief
CRBU
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
20
authors 14d
12
crowd 14d
-1.1σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-12 · now +0.05 (−1 bearish … +1 bullish)
Who spoke12
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @adamfeuerstein | A | -1.03 | 4 | -0.55 |
| @Briefingcom | B | -2.26 | 3 | -0.42 |
| @BPharmCatalyst | C | · | 2 | -0.42 |
| @CHItrader | B | -0.22 | 2 | -0.40 |
| @Tickeron | C | +1.53 | 2 | -0.75 |
| @BenzingaSpain | C | -0.13 | 1 | +0.00 |
| @fwpharma | B | -1.91 | 1 | -0.70 |
| @OpenOutcrier | C | · | 1 | -0.55 |
| @GetPursa | C | +0.10 | 1 | -0.10 |
| @Biotech2k1 | A | +1.11 | 1 | -0.85 |
| @nanalyzetweets | B | +5.59 | 1 | -0.85 |
| @zohmbastic | C | -2.94 | 1 | +0.05 |
Recent signals20of 20 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-12 | @zohmbastic | +0.05 | Notes an unusual volume block, with direction requiring the linked chart. | · | tweet ↗ |
| 2026-10-08 | @CHItrader | -0.40 | Reports multiple equity-rating downgrades; output retains the first six tickers under the schema cap. | · | tweet ↗ |
| 2026-10-07 | @nanalyzetweets | -0.85 | Says CRBU has flamed out and that the outcome seemed inevitable. | · | tweet ↗ |
| 2026-10-07 | @Biotech2k1 | -0.85 | Says CRBU has failed and reinforces avoiding early-stage companies. | · | tweet ↗ |
| 2026-10-07 | @BPharmCatalyst | -0.15 | CRBU begins a sale-or-merger review, pauses two programs and restructures its workforce. | · | tweet ↗ |
| 2026-10-07 | @Tickeron | -0.70 | CRBU discontinued two programs, while Health Canada approved LPCN's oral testosterone therapy. | · | tweet ↗ |
| 2026-10-07 | @Tickeron | -0.80 | CRBU discontinued two CAR-T programs, began a strategic review, and announced a substantial workforce reduction. | · | tweet ↗ |
| 2026-10-07 | @Briefingcom | -0.40 | Leerink and RBC both downgraded CRBU from Outperform and set $1 targets. | · | tweet ↗ |
| 2026-10-07 | @GetPursa | -0.10 | Reports multiple analyst rating actions, led by BofA moving ABEV to Underperform. | · | tweet ↗ |
| 2026-10-07 | @OpenOutcrier | -0.55 | Caribou will halt CAR-T programs and explore a sale after a sharp premarket decline. | · | tweet ↗ |
| 2026-10-07 | @CHItrader | -0.40 | Lists equity-rating downgrades; extraction is capped at six unique tickers. | · | tweet ↗ |
| 2026-10-07 | @Briefingcom | -0.85 | Caribou is discontinuing two programs, effectively halting its clinical pipeline. | · | tweet ↗ |
| 2026-10-07 | @Briefingcom | +0.00 | Lists premarket gap percentages; extraction is capped at the first six tickers. | · | tweet ↗ |
| 2026-10-07 | @fwpharma | -0.70 | Reports Caribou discontinued CAR-T programs and cut staff. | · | tweet ↗ |
| 2026-10-07 | @adamfeuerstein | -0.60 | Caribou was squeezed by weak cell-therapy funding and a shift toward in-vivo delivery. | · | tweet ↗ |
| 2026-10-07 | @adamfeuerstein | -0.90 | Caribou will shut down after failing to finance a Phase 3 lymphoma study. | · | tweet ↗ |
| 2026-10-07 | @adamfeuerstein | +0.10 | Author praises Caribou's CEO while noting layoffs and company setbacks. | · | tweet ↗ |
| 2026-10-07 | @BenzingaSpain | +0.00 | Lists five U.S. stocks to watch during Wednesday's premarket session. | · | tweet ↗ |
| 2026-10-06 | @BPharmCatalyst | -0.70 | Caribou halts two CAR-T programs, begins a strategic review and cuts staff due to constrained finances. | · | tweet ↗ |
| 2026-10-06 | @adamfeuerstein | -0.80 | Caribou could not secure Phase 3 financing and is seeking alternatives or shutting down. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.